Infigratinib for Achondroplasia

Anne Lee Director, Global Patient Advocacy /QED Therapeutics
Daniela Rogoff, MD, Phd Vice President, Clinical Development /QED Therapeutics

The latest information on the development of Infigratinib for patients with achondroplasia. Infigratinib is an orally bioavailable and selective FGFR1/2/3 selective tyrosine kinase inhibitor in development for FGFR-related conditions.